According to DelveInsight, the Postpartum Depression pipeline features over 10 key companies actively engaged in developing more than 10 treatment therapies.
Postpartum Depression Overview:
Postpartum depression (PPD) is a serious mental health condition affecting about 15% of women after giving birth, with potential long-term negative effects on their children. While its symptoms and risk factors are similar to those of general depression, PPD is uniquely triggered by postpartum factors, especially hormonal shifts.
Diagnosis is usually made through a questionnaire in a clinical setting. Common treatments include psychotherapy and antidepressant medication. Symptoms often mirror those of non-postpartum depression—such as persistent sadness, loss of interest, sleep and appetite changes, feelings of worthlessness, poor concentration, and suicidal thoughts—but occur following childbirth. Many women also experience heightened anxiety, and in severe cases, psychotic symptoms like hallucinations or delusions, including harmful commands toward the infant, may be present.
Request for a detailed insights report on Postpartum Depression pipeline insights
"Postpartum Depression Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Postpartum Depression Therapeutics Market.
Key Takeaways from the Postpartum Depression Pipeline Report
-
DelveInsight’s Postpartum Depression (PPD) pipeline report highlights a dynamic landscape, with over 10 active companies working on more than 10 pipeline therapies aimed at improving PPD treatment.
-
Leading players such as GH Research, Reunion Neuroscience, Lipocine, and Brii Biosciences Limited are developing novel drug candidates including RE-104, GH001, and BRII-297, among others.
-
In addition to pharmaceutical innovations, recent research points to the value of lifestyle interventions in managing PPD.
-
A November 2025 study found that engaging in over an hour of moderate-intensity exercise weekly can ease “baby blues” and reduce the risk of major clinical depression in new mothers by half. Gentle walks progressing to moderate activities like brisk walking or water aerobics proved especially helpful, with the greatest benefits seen when exercise was started within 12 weeks after childbirth.
-
Before its approval, zuranolone underwent evaluation in the Phase III SKYLARK trial, which showed rapid and substantial improvements in depressive symptoms. By day 15, 57% of participants taking zuranolone achieved at least a 50% symptom reduction, compared to 38% in the placebo group. These results were pivotal in the FDA’s approval of Zurzuvae as an innovative treatment option for PPD.
Postpartum Depression Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the key companies that are developing therapies in the Postpartum Depression Market.
-
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Postpartum Depression treatment.
-
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Postpartum Depression market.
Download our free sample page report on Postpartum Depression pipeline insights
Postpartum Depression Emerging Drugs
-
RE-104: Reunion Neuroscience
-
GH001: GH Research
-
BRII-297: Brii Bio
Postpartum Depression Companies
More than 10 major companies are actively working on therapies for postpartum depression, with Reunion Neuroscience advancing the most progressed candidate, currently in Phase II clinical trials.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Postpartum Depression pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Postpartum Depression Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Postpartum Depression Therapies and Key Companies: Postpartum Depression Clinical Trials and advancements
Postpartum Depression Pipeline Therapeutic Assessment
• Postpartum Depression Assessment by Product Type
• Postpartum Depression By Stage
• Postpartum Depression Assessment by Route of Administration
• Postpartum Depression Assessment by Molecule Type
Download Postpartum Depression Sample report to know in detail about the Postpartum Depression treatment market @ Postpartum Depression Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Postpartum Depression Current Treatment Patterns
4. Postpartum Depression - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Postpartum Depression Late-Stage Products (Phase-III)
7. Postpartum Depression Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Postpartum Depression Discontinued Products
13. Postpartum Depression Product Profiles
14. Postpartum Depression Key Companies
15. Postpartum Depression Key Products
16. Dormant and Discontinued Products
17. Postpartum Depression Unmet Needs
18. Postpartum Depression Future Perspectives
19. Postpartum Depression Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Postpartum Depression Pipeline Reports Offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
